article thumbnail

Keys to Success in Vaccine Development for Special Populations

PPD

From study participants’ consent, to minimizing the patient and caregiver burden, to planning for different needs at different stages of the pediatric immune system, there are many factors to consider when conducting clinical research with this specific population.

Vaccine 52
article thumbnail

Where is the drug discovery expertise happening in the UK?

Drug Discovery World

The country’s pioneering genomics research, crucial for future drug discovery, is demonstrated by institutes like the Wellcome Sanger Institute and projects like the 100,000 Genomes Project. It’s also where my Co-founder Ed and I met in 2001, at a company called Camitro, from which the foundational technologies of Optibrium emerged.

Drugs 189
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Human neuronal cells: possibilities in drug safety testing

Drug Target Review

1-4 This approach saves time, money, and resources, and ultimately leads to safer medicines going forward to the clinic. CNS-related issues account for nearly a quarter of failures during clinical development, a phase where consequences are high in terms of resources and patient impact. 2001 Sep;24(9):517–26.

Drugs 110
article thumbnail

Article FDA Thank You FDA updates set the stage for broader use of harmonized standards for safety reporting

Agency IQ

Since these issues could occur during the investigational phase of clinical development as well as in the post-marketing setting—and product status could very well differ by country/region—ICH members determined that these guidelines should be developed to facilitate the exchange of information in both settings.

FDA 40
article thumbnail

New horizon for cancer innovation

Drug Discovery World

To achieve this, we have brought our drug discovery sites together under a single leadership team, able to move at speed to partner with academia and industry partners to deliver novel therapies into clinical development. . Recent studies have shown that academic inventors contributed 37% of cancer medicines between 2001-2019.